• You are not logged in.

    Dr n. med. AGNIESZKA SKOTNICKA

    Asystent

    Katedra i Zakład Technologii Postaci Leku
    pokój nr 123 F

    email: askotnic@ump.edu.pl

    dyżury dla studentów: piątek 9.00-10.30

     

     

    BIOGRAPHY

    Agnieszka Skotnicka is a teacher and researcher at the Department of Pharmaceutical Technology, Poznan University of Medical Sciences (PUMS). She is a registered pharmacist with over 10-year’s international experience and in‑depth knowledge in the hospital and clinical pharmacy. Especially, she has a wide scope of expertise in all aspects of clinical trials, aseptic manufacturing, pharmaceutical care services, both in the primary and secondary care settings, oncology and haematology pharmacotherapy.

    She obtained MSc Pharm. in 2005 from Medical University of Gdansk (Gdansk, Poland). After graduation she worked as a Community Pharmacist (Poland, 2005), Senior Oncology Pharmacist, Mercy University Hospital (Cork, Republic of Ireland, 2005-08), Researcher/Teacher, Department of Clinical Pharmacy and Biopharmaceutics, PUMS (Poznan, Poland, 2008-10), Advanced Clinical Pharmacist – Clinical Trials and Research, The James Cook University Hospital (Middlesbrough, UK, 2010-17) and Community Locum Pharmacist (Republic of Ireland and UK; 2005-19). Currently, she practices as a bank Medicines Management Pharmacist & Prescribing Advisor at Powys Teaching Health Board (Wales, UK).

    In addition she has gained significant research experience in the area public health during 8-month visit at School of Pharmacy and Pharmaceutical Sciences at Trinity College Dublin (2019).

    RESEARCH INTERESTS

    Her current research interests focus on the role of the clinical pharmacist and the multidisciplinary team in the provision of collaborative pharmaceutical care in primary and secondary care settings. Research undertaken within this area includes medication adherence in long-term conditions, medicines reconciliation, optimisation and development of public health services.

    She is pursuing PhD under the supervision of Prof. A. Jabłecka (Department of Clinical Pharmacology, PUMS). Her PhD studies encompass the optimisation of pharmacotherapy in elderly patients with heart failure by the pharmacist intervention in the secondary care settings in order to support both patients and prescribers in achieving a treatment pattern that maximizes clinical outcome, cost-effectiveness and minimizes risk. Main research tools include quality of life, adherence and disease-specific clinical outcome measures.

    PUBLIC APPOINTMENTS and COMMITTEES MEMBERSHIP

    Member of Steering Committee and Leader of Ethics Work Package (2018‑present) in the international and intersectoral research project under the Maria Sklodowska-Curie Actions of Horizon 2020 Framework Programme entitled Open Research Biopharmaceutical Internships Support (ORBIS; www.orbisproject.eu), grant agreement No 778051 (2.3 M EUR).

    Expert Member of the North East – Newcastle and North Tyneside Ethics Committee (2013-17; Health Research Authority, UK), reviewing research applications for all phases of clinical trials.

    Expert Member of Research Operational Group at South Tees NHS Foundation Trust (2010-17; Middlesbrough, UK) and Member of Steering Committee of clinical trials entitled: Morphine in simulated haemorrhagic shock (2011-17; South Tees NHS Foundation Trust)

    HEALTHCARE PROFESSIONAL MEMBERSHIPS

    • Registered pharmacist, Polish Pharmaceutical Chamber (2005–present)
    • Registered pharmacist, General Pharmaceutical Council UK (2010–present)
    • Registered pharmacist, Pharmaceutical Society of Ireland (2005–present)

    SELECTED PUBLICATIONS AND CONFERENCE PRESENTATIONS

    FOCUS Trial Collaboration [1297 Collaborators, M. Dennis, et al.A. Skotnicka…]. Effects of fluoxetine on functional outcomes after acute stroke (FOCUS): a pragmatic, double-blind, randomised, controlled trial, The Lancet  2019, 393.10168, p. 265-74
    G. Major, et al., on behalf of the RAPID Collaboration Group [242 Collaborators, …A. Skotnicka…]. Follow-on RifAximin for the Prevention of recurrence following standard treatment of Infection with Clostridium Difficile (RAPID): a randomised placebo controlled trial, Gut 2019, 68.7, p. 1224-31
    G. E. Thwaites, et al., on behalf of the United Kingdom Clinical Infection Research Group (UKCIRG) [452 Collaborators, …A. Skotnicka…] Adjunctive rifampicin for Staphylococcus aureus bacteraemia (ARREST): a multicentre, randomised, double-blind, placebo-controlled trial, The Lancet 2018, 391.10121, p. 668-78
    A. Skotnicka, A Jabłecka. The current guidelines for management of heart failure –part II (in Polish), Contemporary Pharmacy 2018, 11, p. 231-38
    A. Skotnicka, A Jabłecka. The current guidelines for management of heart failure – part I (in Polish), Contemporary Pharmacy 2018, 11, p. 133-39
    A. Skotnicka, M. Skotnicki, M. Waszyk-Nowaczyk, I. Miechowicz, J. Lulek, E. Grzeskowiak. Patient medication adherence: a pilot study in Poland, Abstracts of the 2010 RPS Conference, Int. J. Pharm. Pract. 2010 vol. 18 suppl. 2 p. 82
    M. Skotnicki, A. Skotnicka, E. Grzeskowiak, J. Lulek. Non-adherence to treatment regimen as a contemporary pharmacotherapy problem (in Polish), Pharmaceutical Scientific Review 2010, 2, p. 8-14
    A. Skotnicka, E. Szalek, E. Grzeskowiak. Drug neurotoxicity – current problem of pharmacotherapy (in Polish) Pharmaceutical Scientific Review 2009, 6, p. 18-21
    A. Skotnicka, E. Grzeskowiak. Neuroprotective agents with a potential application in the chemotherapy-induced peripheral neuropathy (in Polish) Contemporary Pharmacy 2009, 2, p 36-41